Wordt geladen...
Effect of Rimonabant on Glycemic Control in Insulin-Treated Type 2 Diabetes: The ARPEGGIO Trial
OBJECTIVE: To examine the efficacy and safety of rimonabant, a selective cannabinoid receptor type-1 antagonist, in patients with type 2 diabetes receiving insulin monotherapy. RESEARCH DESIGN AND METHODS: Patients (n = 368; A1C ≥7%) were randomized to 20 mg/day rimonabant or placebo in this 48-week...
Bewaard in:
| Hoofdauteurs: | , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
American Diabetes Association
2010
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2827517/ https://ncbi.nlm.nih.gov/pubmed/20009090 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc09-0455 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|